{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(5)"],"submitter":["Xu B"],"pubmed_abstract":["Acute myeloid leukemia (AML) is a heterogeneous malignancy. Despite the advances in past decades, the clinical outcomes of AML patients remain poor. Leukemia stem cells (LSCs) is the major cause of the recurrence of AML even after aggressive treatment making, promoting development of LSC-targeted agents is an urgent clinical need. Although the antitumor activity of disulfiram (DS), an approved anti-alcoholism drug, has been demonstrated in multiple types of tumors including hematological malignancies such as AML, it remains unknown whether this agent would also be able to target cancer stem cells like LSCs. Here, we report the in vitro and in vivo activity of DS in combination with copper (Cu) against CD34+/CD38+ leukemia stem-like cells sorted from KG1α and Kasumi-1 AML cell lines, as wel"],"journal":["Cell death & disease"],"pagination":["e2797"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5520701"],"repository":["biostudies-literature"],"pubmed_title":["Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2."],"pmcid":["PMC5520701"],"pubmed_authors":["Chen K","Dong H","Xu B","Wang S","Zha J","Wang W","Li R","He L","Deng M","Kannappan V"],"additional_accession":[]},"is_claimable":false,"name":"Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.","description":"Acute myeloid leukemia (AML) is a heterogeneous malignancy. Despite the advances in past decades, the clinical outcomes of AML patients remain poor. Leukemia stem cells (LSCs) is the major cause of the recurrence of AML even after aggressive treatment making, promoting development of LSC-targeted agents is an urgent clinical need. Although the antitumor activity of disulfiram (DS), an approved anti-alcoholism drug, has been demonstrated in multiple types of tumors including hematological malignancies such as AML, it remains unknown whether this agent would also be able to target cancer stem cells like LSCs. Here, we report the in vitro and in vivo activity of DS in combination with copper (Cu) against CD34+/CD38+ leukemia stem-like cells sorted from KG1α and Kasumi-1 AML cell lines, as wel","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 May","modification":"2025-04-19T21:11:24.902Z","creation":"2019-03-27T00:09:04Z"},"accession":"S-EPMC5520701","cross_references":{"pubmed":["28518151"],"doi":["10.1038/cddis.2017.176"]}}